Invesco Mortgage Capital (IVR) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
2 Feb, 2026Executive summary
Book value per common share increased 3.7% to $8.72, with an 8.0% economic return and a dividend raised to $0.36 per share in Q4 2025.
Net income per common share was $0.68, down from $0.74 in Q3 2025, and earnings available for distribution per share were $0.56.
Leverage increased to 7.0x, reflecting a constructive investment environment.
Agency mortgages outperformed Treasuries, supported by Fed rate cuts, strong economic growth, and GSE purchases.
The company announced a shift from quarterly to monthly dividends, with the first monthly dividend of $0.12 per share declared in January 2026.
Financial highlights
The investment portfolio totaled $6.3 billion at year-end, with $5.4 billion in Agency RMBS and $900 million in Agency CMBS.
Liquidity position remained strong with $453.3 million in unrestricted cash and unencumbered assets.
Total interest income was $77.9 million, and net interest income rose to $21.3 million.
Raised $7.2 million through at-the-market common stock program and repurchased $1.8 million of Series C Preferred Stock.
Repurchase agreements outstanding totaled $5.6 billion, in line with asset growth.
Outlook and guidance
Management remains constructive on Agency RMBS due to lower volatility and broadening demand, but sees near-term risks as balanced after strong performance.
Market expects an additional 50 basis points of Fed cuts through 2026.
Agency CMBS is expected to continue offering attractive risk-adjusted yields and diversification benefits.
Forward-looking statements caution about risks related to market conditions, interest rates, spreads, and prepayment trends.
Latest events from Invesco Mortgage Capital
- Director elections, executive pay, and auditor ratification up for vote at the 2026 annual meeting.IVR
Proxy filing20 Mar 2026 - Board refreshment, strong returns, and robust governance highlight this year's proxy agenda.IVR
Proxy filing20 Mar 2026 - Book value per share fell 8% in Q2, but distributable earnings and dividend remained stable.IVR
Q2 20241 Feb 2026 - Q3 2024 saw a return to profitability, higher book value, and a 5.4% economic return.IVR
Q3 202416 Jan 2026 - Book value dropped 4.8% in Q4, with net loss and improved capital structure amid volatility.IVR
Q4 202423 Dec 2025 - Shelf registration allows up to $650M in securities for REIT investment and capital needs.IVR
Registration Filing16 Dec 2025 - Board seeks approval for director elections, executive pay, and auditor ratification amid strong governance.IVR
Proxy Filing1 Dec 2025 - Director elections, executive pay, and auditor ratification up for vote at May 2025 meeting.IVR
Proxy Filing1 Dec 2025 - Earnings rebounded in Q1 2025, but book value fell as volatility and risks persisted.IVR
Q1 202525 Nov 2025